Ultragenyx Pharmaceutical Faces Class Action Lawsuit for Securities Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy RARE?
Source: Globenewswire
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Ultragenyx Pharmaceutical for securities violations related to transactions from August 3, 2023, to December 26, 2025, urging affected investors to contact the firm by April 6, 2026, to participate.
- False Statements Exposed: The complaint alleges that Ultragenyx made false and misleading statements regarding its drug candidate's effects on Osteogenesis Imperfecta patients, leading to significant investor losses once the truth was revealed.
- Clinical Trial Failure: The company's Phase III ORBIT study failed to achieve a statistically significant reduction in annualized fracture rate, highlighting its misjudgment of the drug's efficacy and further eroding investor confidence.
- Legal Implications: Until the class action is certified, investors are not represented by an attorney, and those who choose not to act may remain absent class members, risking their ability to recover losses.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RARE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RARE
Wall Street analysts forecast RARE stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 20.460
Low
35.00
Averages
61.65
High
120.00
Current: 20.460
Low
35.00
Averages
61.65
High
120.00
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ultragenyx Pharmaceutical Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Ultragenyx Pharmaceutical for securities violations related to transactions from August 3, 2023, to December 26, 2025, urging affected investors to contact the firm by April 6, 2026, to participate.
- False Statements Exposed: The complaint alleges that Ultragenyx made false and misleading statements regarding its drug candidate's effects on Osteogenesis Imperfecta patients, leading to significant investor losses once the truth was revealed.
- Clinical Trial Failure: The company's Phase III ORBIT study failed to achieve a statistically significant reduction in annualized fracture rate, highlighting its misjudgment of the drug's efficacy and further eroding investor confidence.
- Legal Implications: Until the class action is certified, investors are not represented by an attorney, and those who choose not to act may remain absent class members, risking their ability to recover losses.
See More
Ultragenyx Faces Class Action Lawsuit Over Misleading Statements
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that investors who purchased Ultragenyx (NASDAQ:RARE) common stock between August 3, 2023, and December 26, 2025, can apply to be lead plaintiff in the class action lawsuit, with a deadline of April 6, 2026, highlighting investor concerns over potential legal risks.
- False Statement Allegations: The lawsuit alleges that Ultragenyx and its executives made false and misleading statements during the class period, failing to disclose risks associated with their Osteogenesis Imperfecta (OI) studies, which may have misled investors about the company's prospects and impacted stock prices.
- Stock Price Volatility: Following the July 9, 2025, announcement that the Phase III Orbit study failed to achieve statistical significance, Ultragenyx's stock fell over 25%; on December 29, 2025, the stock plummeted more than 42% after the company revealed that its Phase III studies did not meet primary endpoints, reflecting market disappointment in the company's performance.
- Legal Process Implications: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Ultragenyx stock during the class period can seek lead plaintiff status, representing other investors in the lawsuit, which could have significant implications for the company's future legal and financial standing.
See More
Ultragenyx Securities Class Action Reminder
- Filing Deadline: ClaimsFiler reminds investors that those who purchased Ultragenyx shares between August 3, 2023, and December 26, 2025, must file lead plaintiff applications by April 6, 2026, to participate in the securities class action lawsuit, ensuring their rights are protected.
- Stock Price Plunge: Following the December 26, 2025 announcement that the Phase 3 trials for setrusumab failed to show significant efficacy, Ultragenyx's stock price plummeted approximately 42% from $34.19 to $19.72 within three days, indicating a severe loss of investor confidence and market value.
- Legal Allegations: The lawsuit alleges that Ultragenyx and certain executives failed to disclose material information during the class period, violating federal securities laws, which could expose the company to greater legal and financial risks, potentially impacting future operations and investor trust.
- Legal Support Information: Investors can visit ClaimsFiler for more information about the lawsuit and contact Kahn Swick & Foti, LLC for legal options, ensuring they receive necessary support and guidance throughout the legal process.
See More
Ultragenyx Pharmaceutical Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to potentially receive compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that defendants provided materially false and misleading information regarding the expected results of setrusumab (UX 143) in Phase III Orbit and Cosmic studies, leading investors to purchase shares at artificially inflated prices, resulting in damages.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, highlighting its successful track record, which investors should consider when selecting legal counsel.
- Investor Action Recommendation: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on joining the lawsuit, noting that no class has been certified yet, allowing them to choose their legal representation or remain absent from the class.
See More
Faruqi & Faruqi Investigates Ultragenyx Securities Litigation
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Ultragenyx Pharmaceutical, urging investors who purchased shares between August 3, 2023, and December 26, 2025, to apply as lead plaintiffs by the April 6, 2026 deadline.
- Stock Price Volatility: Following Ultragenyx's announcement on July 9, 2025, that its Phase III Orbit study failed to achieve statistical significance, the stock plummeted over 25%; further confirmation on December 29, 2025, that the studies did not meet primary endpoints led to an additional 42% drop, reflecting severe market concerns about the company's future.
- False Statement Allegations: The complaint alleges that Ultragenyx and its executives violated federal securities laws by making false or misleading statements regarding the effects of setrusumab on patients with Osteogenesis Imperfecta, failing to adequately disclose the risks associated with the study results.
- Investor Rights Protection: Faruq & Faruqi encourages anyone with information regarding Ultragenyx's conduct, including whistleblowers and former employees, to contact the firm directly to better protect investors' legal rights.
See More
Class Action Lawsuit Filed Against Ultragenyx Pharmaceutical Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Ultragenyx Pharmaceutical Inc. and certain officers, seeking damages for investors who purchased securities between August 3, 2023, and December 26, 2025.
- Allegations: The complaint alleges that throughout the class period, defendants made false and/or misleading statements and failed to disclose risks associated with the Phase III Orbit study, misleading investors regarding the treatment's effectiveness for Osteogenesis Imperfecta patients.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by April 6, 2026, allowing them to share in any recovery without needing to serve as lead plaintiffs, thus broadening participation in the lawsuit.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman, LLC specializes in securities fraud class actions and has recovered hundreds of millions for investors nationwide, emphasizing their commitment to restoring investor capital and ensuring corporate accountability.
See More
Ultragenyx Pharmaceutical Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Ultragenyx Pharmaceutical for securities violations related to transactions from August 3, 2023, to December 26, 2025, urging affected investors to contact the firm by April 6, 2026, to participate.
- False Statements Exposed: The complaint alleges that Ultragenyx made false and misleading statements regarding its drug candidate's effects on Osteogenesis Imperfecta patients, leading to significant investor losses once the truth was revealed.
- Clinical Trial Failure: The company's Phase III ORBIT study failed to achieve a statistically significant reduction in annualized fracture rate, highlighting its misjudgment of the drug's efficacy and further eroding investor confidence.
- Legal Implications: Until the class action is certified, investors are not represented by an attorney, and those who choose not to act may remain absent class members, risking their ability to recover losses.
See More
Ultragenyx Faces Class Action Lawsuit Over Misleading Statements
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that investors who purchased Ultragenyx (NASDAQ:RARE) common stock between August 3, 2023, and December 26, 2025, can apply to be lead plaintiff in the class action lawsuit, with a deadline of April 6, 2026, highlighting investor concerns over potential legal risks.
- False Statement Allegations: The lawsuit alleges that Ultragenyx and its executives made false and misleading statements during the class period, failing to disclose risks associated with their Osteogenesis Imperfecta (OI) studies, which may have misled investors about the company's prospects and impacted stock prices.
- Stock Price Volatility: Following the July 9, 2025, announcement that the Phase III Orbit study failed to achieve statistical significance, Ultragenyx's stock fell over 25%; on December 29, 2025, the stock plummeted more than 42% after the company revealed that its Phase III studies did not meet primary endpoints, reflecting market disappointment in the company's performance.
- Legal Process Implications: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Ultragenyx stock during the class period can seek lead plaintiff status, representing other investors in the lawsuit, which could have significant implications for the company's future legal and financial standing.
See More
Ultragenyx Securities Class Action Reminder
- Filing Deadline: ClaimsFiler reminds investors that those who purchased Ultragenyx shares between August 3, 2023, and December 26, 2025, must file lead plaintiff applications by April 6, 2026, to participate in the securities class action lawsuit, ensuring their rights are protected.
- Stock Price Plunge: Following the December 26, 2025 announcement that the Phase 3 trials for setrusumab failed to show significant efficacy, Ultragenyx's stock price plummeted approximately 42% from $34.19 to $19.72 within three days, indicating a severe loss of investor confidence and market value.
- Legal Allegations: The lawsuit alleges that Ultragenyx and certain executives failed to disclose material information during the class period, violating federal securities laws, which could expose the company to greater legal and financial risks, potentially impacting future operations and investor trust.
- Legal Support Information: Investors can visit ClaimsFiler for more information about the lawsuit and contact Kahn Swick & Foti, LLC for legal options, ensuring they receive necessary support and guidance throughout the legal process.
See More
Ultragenyx Pharmaceutical Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to potentially receive compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that defendants provided materially false and misleading information regarding the expected results of setrusumab (UX 143) in Phase III Orbit and Cosmic studies, leading investors to purchase shares at artificially inflated prices, resulting in damages.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, highlighting its successful track record, which investors should consider when selecting legal counsel.
- Investor Action Recommendation: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on joining the lawsuit, noting that no class has been certified yet, allowing them to choose their legal representation or remain absent from the class.
See More
Faruqi & Faruqi Investigates Ultragenyx Securities Litigation
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Ultragenyx Pharmaceutical, urging investors who purchased shares between August 3, 2023, and December 26, 2025, to apply as lead plaintiffs by the April 6, 2026 deadline.
- Stock Price Volatility: Following Ultragenyx's announcement on July 9, 2025, that its Phase III Orbit study failed to achieve statistical significance, the stock plummeted over 25%; further confirmation on December 29, 2025, that the studies did not meet primary endpoints led to an additional 42% drop, reflecting severe market concerns about the company's future.
- False Statement Allegations: The complaint alleges that Ultragenyx and its executives violated federal securities laws by making false or misleading statements regarding the effects of setrusumab on patients with Osteogenesis Imperfecta, failing to adequately disclose the risks associated with the study results.
- Investor Rights Protection: Faruq & Faruqi encourages anyone with information regarding Ultragenyx's conduct, including whistleblowers and former employees, to contact the firm directly to better protect investors' legal rights.
See More
Class Action Lawsuit Filed Against Ultragenyx Pharmaceutical Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Ultragenyx Pharmaceutical Inc. and certain officers, seeking damages for investors who purchased securities between August 3, 2023, and December 26, 2025.
- Allegations: The complaint alleges that throughout the class period, defendants made false and/or misleading statements and failed to disclose risks associated with the Phase III Orbit study, misleading investors regarding the treatment's effectiveness for Osteogenesis Imperfecta patients.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by April 6, 2026, allowing them to share in any recovery without needing to serve as lead plaintiffs, thus broadening participation in the lawsuit.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman, LLC specializes in securities fraud class actions and has recovered hundreds of millions for investors nationwide, emphasizing their commitment to restoring investor capital and ensuring corporate accountability.
See More
